Category Archives: Other
Reviews that are lab-based (e.g. genes, pharmaceuticals) or on unique groups of people (e.g. fishermen, nurses)
Safety of oral tenofovir disoproxil fumarate-based pre-exposure prophylaxis for HIV prevention
INTRODUCTION: Tenofovir disoproxil fumarate (TDF)-based pre-exposure prophylaxis is a novel HIV prevention strategy for individuals at increased sexual risk for HIV infection. For any biomedical prevention intervention, the bar for...
Review of functional MRI in HIV: Effects of aging and medication
HIV-associated neurocognitive disorder (HAND) is a frequently occurring comorbidity of HIV infection. Evidence suggests this condition starts subclinical before a progression to a symptomatic stage. Blood oxygenated level dependent (BOLD)...
Atazanavir and cardiovascular risk among human immunodeficiency virus-infected patients: A systematic review
INTRODUCTION: Patients with human immunodeficiency virus (HIV) infection have an increased risk of cardiovascular disease (CVD). While viral suppression with antiretroviral therapy decreases CVD risk overall, several studies have suggested...
A comprehensive review of reviews of school-based interventions to improve sexual-health
OBJECTIVE: To systematically review systematic reviews of school-based sexual-health and relationship Education (SHRE) programmes and, thereby, identify interventions and intervention components that promote reductions in risky sexual behaviour among young...
The contribution of unsafe blood transfusion to human immunodeficiency virus incidence in sub-Saharan Africa: Reexamination of the 5% to 10% convention
BACKGROUND: Historical estimates have attributed 5% to 10% of new human immunodeficiency virus (HIV) infections in sub-Saharan Africa (SSA) to unsafe blood transfusions. Although frequently cited, the validity of this...
Dolutegravir(DTG, S/GSK1349572) combined with other ARTs is superior to RAL- or EFV-based regimens for treatment of HIV-1 infection: A meta-analysis of randomized controlled trials
BACKGROUND: The first-generation integrase inhibitors (INIs) raltegravir (RAL) and elvitegravir (EVG) have shown efficacy against HIV infection, but they have the limitations of once-more daily dosing and extensive cross-resistance. Dolutegravir...
The clinical usefulness of tuberculin skin test versus interferon-gamma release assays for diagnosis of latent tuberculosis in HIV patients: A meta-analysis
BACKGROUND: Accurate diagnosis of latent tuberculosis infection (LTBI) is becoming increasingly concerning due to the increasing the HIV epidemic, which have increased the risk for reactivation to active tuberculosis (TB)...
Assessing the impact of defining a global priority research agenda to address HIV-associated tuberculosis
OBJECTIVES: In 2010, the WHO issued 77 priority research questions (PRQs) to address HIV-associated TB. Objective of the this study was to assess the impact of defining the research agenda...
A very low number of national adaptations of the World Health Organization guidelines for HIV and tuberculosis reported their processes
BACKGROUND: Low- and middle-income countries adapt World Health Organization (WHO) guidelines instead of de novo development for financial, epidemiologic, sociopolitical, cultural, organizational, and other reasons. OBJECTIVE: To systematically evaluate reported...
Therapy-emergent drug resistance to integrase strand transfer inhibitors in HIV-1 patients: A subgroup meta-analysis of clinical trials
BACKGROUND: Integrase strand transfer inhibitors (INSTIs) are a novel class of anti-HIV agents that show high activity in inhibiting HIV-1 replication. Currently, licensed INSTIs include raltegravir (RAL), elvitegravir (EVG) and...
